{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T10:20:37Z","timestamp":1794738037651,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012036","name":"Lotte Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Prediction of responses to chimeric antigen receptor (CAR)-T cell therapies is essential to maximize their therapeutic efficacy for diffuse large B-cell lymphoma (DLBCL). While several tumor-intrinsic risk factors of resistance and\/or early relapse have been identified, clinically useful markers that determine potential activity of CAR-T cells have not been fully investigated. T-cell property at the time of leukapheresis may serve as such a marker. Therefore, we evaluated the clinical impact of CD3\n                    <jats:sup>+<\/jats:sup>\n                    cell count in peripheral blood at leukapheresis on clinical outcomes of CAR-T cell therapy. In total, 44 patients with relapsed or refractory (r\/r) DLBCL who received tisagenlecleucel at Kyoto University Hospital were included. According to CD3\n                    <jats:sup>+<\/jats:sup>\n                    cell counts, patients were categorized into CD3\n                    <jats:sup>LOW<\/jats:sup>\n                    and CD3\n                    <jats:sup>HIGH<\/jats:sup>\n                    groups with a threshold of 553\/\u03bcL, based on receiver operating characteristic curve analysis. 1-year progression-free survival was significantly higher in the CD3\n                    <jats:sup>HIGH<\/jats:sup>\n                    group than the CD3\n                    <jats:sup>LOW<\/jats:sup>\n                    group (68.3% vs. 17.3%; adjusted hazard ratio [aHR], 0.37; p\u2009=\u20090.042). Overall survival was also superior in the CD3\n                    <jats:sup>HIGH<\/jats:sup>\n                    group (aHR, 0.24; p\u2009=\u20090.043). Moreover, higher CD3\n                    <jats:sup>+<\/jats:sup>\n                    cell counts at leukapheresis were associated with significantly higher lymphocyte counts in peripheral blood at day 7 after CAR-T cell infusion (median 860 vs. 420\/\u03bcL, P\u2009=\u20090.021), suggesting more extensive expansion of infused CAR-T cells in vivo. In conclusion, we demonstrated that the CD3\n                    <jats:sup>+<\/jats:sup>\n                    cell count at leukapheresis predicts both expansion of CAR-T cells after infusion and outcomes of CAR-T cell therapy, and are useful for building comprehensive therapeutic strategies at the time of leukapheresis.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-23589-9","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T12:04:58Z","timestamp":1667563498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy"],"prefix":"10.1038","volume":"12","author":[{"given":"Fumiya","family":"Wada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyasu","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisaki","family":"Mizumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Nishikori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouhei","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"issue":"16","key":"23589_CR1","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood 130(16), 1800\u20131808 (2017).","journal-title":"Blood"},{"issue":"19","key":"23589_CR2","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","volume":"4","author":"D Sermer","year":"2020","unstructured":"Sermer, D. et al. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv. 4(19), 4669\u20134678 (2020).","journal-title":"Blood Adv."},{"issue":"26","key":"23589_CR3","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377(26), 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"23589_CR4","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini, M. C. et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 4(21), 5414\u20135424 (2020).","journal-title":"Blood Adv."},{"issue":"1","key":"23589_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380(1), 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"23589_CR6","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","volume":"4","author":"EA Dean","year":"2020","unstructured":"Dean, E. A. et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4(14), 3268\u20133276 (2020).","journal-title":"Blood Adv."},{"issue":"22","key":"23589_CR7","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino, L. et al. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 4(22), 5607\u20135615 (2020).","journal-title":"Blood Adv."},{"issue":"4","key":"23589_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.21.02143","volume":"40","author":"R Shouval","year":"2022","unstructured":"Shouval, R. et al. Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy. J. Clin. Oncol. 40(4), 369\u2013381 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"23589_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-20-0037","volume":"10","author":"MR Green","year":"2020","unstructured":"Green, M. R. & Neelapu, S. S. Not so FASt: Tumor cells resisting death drive CAR T-cell dysfunction. Cancer Discov. 10(4), 492\u2013494 (2020).","journal-title":"Cancer Discov."},{"key":"23589_CR10","unstructured":"Swerdlow, S.H.C.E., & Harris, N.L. et al. (Ed.) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edn. (International Agency for Research on Cancer (IARC), 2017)."},{"issue":"5","key":"23589_CR11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson, B. D. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25(5), 579\u2013586 (2007).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"23589_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 48(3), 452\u2013458 (2013).","journal-title":"Bone Marrow Transplant."},{"key":"23589_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.780442","volume":"12","author":"PH Mehta","year":"2021","unstructured":"Mehta, P. H. et al. T cell fitness and autologous CAR T cell therapy in haematologic malignancy. Front. Immunol. 12, 780442 (2021).","journal-title":"Front. Immunol."},{"key":"23589_CR14","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.3389\/fimmu.2020.02153","volume":"11","author":"RE Cooke","year":"2020","unstructured":"Cooke, R. E. et al. Conventional treatment for multiple myeloma drives premature aging phenotypes and metabolic dysfunction in T cells. Front. Immunol. 11, 2153 (2020).","journal-title":"Front. Immunol."},{"key":"23589_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.86","volume":"5","author":"H Saito","year":"2015","unstructured":"Saito, H. et al. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Blood Cancer J. 5, e362 (2015).","journal-title":"Blood Cancer J."},{"issue":"8","key":"23589_CR16","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/leu.2016.84","volume":"30","author":"H Suen","year":"2016","unstructured":"Suen, H. et al. Multiple myeloma causes clonal T-cell immunosenescence: Identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia 30(8), 1716\u20131724 (2016).","journal-title":"Leukemia"},{"issue":"3","key":"23589_CR17","first-page":"163","volume":"62","author":"T Jo","year":"2021","unstructured":"Jo, T. et al. Clinical experience of leukapheresis for CD19 CAR-T cell therapy. Rinsho Ketsueki 62(3), 163\u2013169 (2021).","journal-title":"Rinsho Ketsueki"},{"issue":"2","key":"23589_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1385\/MB:15:2:133","volume":"15","author":"I Riviere","year":"2000","unstructured":"Riviere, I., Gallardo, H. F., Hagani, A. B. & Sadelain, M. Retroviral-mediated gene transfer in primary murine and human T-lymphocytes. Mol. Biotechnol. 15(2), 133\u2013142 (2000).","journal-title":"Mol. Biotechnol."},{"issue":"19","key":"23589_CR19","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood 137(19), 2621\u20132633 (2021).","journal-title":"Blood"},{"issue":"19","key":"23589_CR20","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1182\/blood.2020010462","volume":"137","author":"P Strati","year":"2021","unstructured":"Strati, P. & Neelapu, S. S. CAR-T failure: Beyond antigen loss and T cells. Blood 137(19), 2567\u20132568 (2021).","journal-title":"Blood"},{"issue":"Suppl 1","key":"23589_CR21","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1182\/blood-2021-151295","volume":"138","author":"RGA Bansal","year":"2021","unstructured":"Bansal, R. G. A. et al. Peak absolute lymphocyte count post CAR-T is associated with clinical response and survival outcome in aggressive lymphoma. Blood 138(Suppl 1), 3856 (2021).","journal-title":"Blood"},{"issue":"8","key":"23589_CR22","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1182\/bloodadvances.2020004038","volume":"5","author":"S Faude","year":"2021","unstructured":"Faude, S. et al. Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse. Blood Adv. 5(8), 2128\u20132136 (2021).","journal-title":"Blood Adv."},{"issue":"21","key":"23589_CR23","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","volume":"130","author":"KT Mueller","year":"2017","unstructured":"Mueller, K. T. et al. Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood 130(21), 2317\u20132325 (2017).","journal-title":"Blood"},{"issue":"19","key":"23589_CR24","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","volume":"3","author":"AL Garfall","year":"2019","unstructured":"Garfall, A. L. et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 3(19), 2812\u20132815 (2019).","journal-title":"Blood Adv."},{"key":"23589_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/jci.insight.134612","volume":"5","author":"PH Chen","year":"2020","unstructured":"Chen, P. H. et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight 5, 12 (2020).","journal-title":"JCI Insight"},{"issue":"12","key":"23589_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1172\/JCI150807","volume":"132","author":"S Arcangeli","year":"2022","unstructured":"Arcangeli, S. et al. CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J. Clin. Invest. 132(12), 3 (2022).","journal-title":"J. Clin. Invest."},{"issue":"6","key":"23589_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s43018-021-00207-7","volume":"2","author":"L Biasco","year":"2021","unstructured":"Biasco, L. et al. Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. Nat. Cancer. 2(6), 629\u2013642 (2021).","journal-title":"Nat. Cancer."},{"issue":"12","key":"23589_CR28","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26(12), 1878\u20131887 (2020).","journal-title":"Nat. Med."},{"issue":"8","key":"23589_CR29","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1182\/blood-2018-01-828343","volume":"132","author":"J Rossi","year":"2018","unstructured":"Rossi, J. et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood 132(8), 804\u2013814 (2018).","journal-title":"Blood"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23589-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23589-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23589-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T12:53:42Z","timestamp":1667566422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23589-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["23589"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-23589-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,4]]},"assertion":[{"value":"2 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18696"}}